EASL Congress 2025

IF 38.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Lancet Gastroenterology & Hepatology Pub Date : 2025-06-04 DOI:10.1016/s2468-1253(25)00168-2

Hugh Thomas

{"title":"EASL Congress 2025","authors":"Hugh Thomas","doi":"10.1016/s2468-1253(25)00168-2","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Undiagnosed liver fibrosis in Europe</h2>Undiagnosed liver fibrosis is common in the European adult population, primarily driven by metabolic risk factors and alcohol consumption, according to the prospective LIVERSCREEN cohort study. Isabel Graupera and colleagues enrolled 30 541 adults older than 40 years without known liver disease from nine European countries. Liver fibrosis was assessed by liver stiffness measurement (LSM) using vibration-controlled transient elastography, with the primary outcome being the prevalence of LSM of 8</section></section><section><section><h2>Long-term albumin in cirrhosis</h2>Long-term albumin (LTA) therapy did not significantly improve 1-year transplantation-free survival in patients with cirrhosis, acute decompensation, and existing or previous ascites, according to the PRECIOSA trial. Jacqueline G O’Leary and colleagues randomly assigned 410 patients to receive standard medical treatment plus LTA (1·5 g/kg every 10 days for up to 12 months; n=203) or standard medical treatment alone (n=207). At 1 year, transplantation-free survival (the primary endpoint) was</section></section><section><section><h2>Resmetirom in MASH cirrhosis</h2>2 years of treatment with resmetirom improved liver stiffness and reduced portal hypertension risk in patients with compensated cirrhosis related to metabolic dysfunction-associated steatohepatitis, according to an open-label trial analysis. Naim Alkhouri and colleagues assessed 122 patients with Child–Pugh A MASH cirrhosis who were treated with 80 mg resmetirom daily for up to 2 years. The primary endpoint was safety and tolerability: 113 (93%) patients completed 2 years of treatment in the</section></section><section><section><h2>Norucholic acid in primary sclerosing cholangitis</h2>Norucholic acid treatment for 96 weeks improved biochemical markers and reduced fibrosis progression in patients with primary sclerosing cholangitis (PSC), according to a pivotal phase 3 trial. Michael Trauner and colleagues randomly assigned (2:1) 301 adult patients with PSC and an alkaline phosphatase (ALP) greater than 1.5 times the upper limit of normal (ULN) to receive 1500 mg norucholic acid once daily (n=205) or placebo (n=96). The combined primary endpoint at 96 weeks was partial</section></section>","PeriodicalId":56028,"journal":{"name":"Lancet Gastroenterology & Hepatology","volume":"61 1","pages":"619"},"PeriodicalIF":38.6000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Gastroenterology & Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2468-1253(25)00168-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Undiagnosed liver fibrosis in Europe

Undiagnosed liver fibrosis is common in the European adult population, primarily driven by metabolic risk factors and alcohol consumption, according to the prospective LIVERSCREEN cohort study. Isabel Graupera and colleagues enrolled 30 541 adults older than 40 years without known liver disease from nine European countries. Liver fibrosis was assessed by liver stiffness measurement (LSM) using vibration-controlled transient elastography, with the primary outcome being the prevalence of LSM of 8

Long-term albumin in cirrhosis

Long-term albumin (LTA) therapy did not significantly improve 1-year transplantation-free survival in patients with cirrhosis, acute decompensation, and existing or previous ascites, according to the PRECIOSA trial. Jacqueline G O’Leary and colleagues randomly assigned 410 patients to receive standard medical treatment plus LTA (1·5 g/kg every 10 days for up to 12 months; n=203) or standard medical treatment alone (n=207). At 1 year, transplantation-free survival (the primary endpoint) was

Resmetirom in MASH cirrhosis

2 years of treatment with resmetirom improved liver stiffness and reduced portal hypertension risk in patients with compensated cirrhosis related to metabolic dysfunction-associated steatohepatitis, according to an open-label trial analysis. Naim Alkhouri and colleagues assessed 122 patients with Child–Pugh A MASH cirrhosis who were treated with 80 mg resmetirom daily for up to 2 years. The primary endpoint was safety and tolerability: 113 (93%) patients completed 2 years of treatment in the

Norucholic acid in primary sclerosing cholangitis

Norucholic acid treatment for 96 weeks improved biochemical markers and reduced fibrosis progression in patients with primary sclerosing cholangitis (PSC), according to a pivotal phase 3 trial. Michael Trauner and colleagues randomly assigned (2:1) 301 adult patients with PSC and an alkaline phosphatase (ALP) greater than 1.5 times the upper limit of normal (ULN) to receive 1500 mg norucholic acid once daily (n=205) or placebo (n=96). The combined primary endpoint at 96 weeks was partial

查看原文本刊更多论文

2025年EASL大会

根据前瞻性livergreen队列研究，未确诊的肝纤维化在欧洲成年人中很常见，主要由代谢危险因素和酒精消费驱动。Isabel Graupera及其同事从9个欧洲国家招募了30541名40岁以上无已知肝病的成年人。使用振动控制的瞬时弹性成像，通过肝刚度测量（LSM）评估肝纤维化，主要结果是肝硬化患者LSM的发生率。根据PRECIOSA试验，长期白蛋白（LTA）治疗并没有显著提高肝硬化、急性代偿失代偿和现有或既往腹水患者的1年无移植生存率。Jacqueline G O 'Leary及其同事随机分配410名患者接受标准药物治疗加LTA(每10天1.5 G /kg，持续12个月；N =203)或单独进行标准药物治疗（N =207）。一项开放标签试验分析显示，雷司替康治疗2年后，代偿性肝硬化伴代谢功能障碍相关脂肪性肝炎患者的肝僵硬度得到改善，门脉高压风险降低。Naim Alkhouri及其同事评估了122例Child-Pugh A型MASH肝硬化患者，这些患者每天服用80毫克雷司美替治疗2年。主要终点是安全性和耐受性：113例（93%）患者完成了2年的诺磺胆酸治疗原发性硬化性胆管炎（PSC）患者96周的诺磺胆酸治疗改善了生化指标并减少了纤维化进展。Michael Trauner及其同事随机分配（2:1）301例PSC和碱性磷酸酶（ALP）高于正常上限（ULN） 1.5倍的成年患者，每天一次接受1500mg去甲胆酸（n=205）或安慰剂（n=96）。96周时的联合主要终点是部分终点

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lancet Gastroenterology & Hepatology Medicine-Hepatology

CiteScore

50.30

自引率

1.10%

发文量

期刊介绍： The Lancet Gastroenterology & Hepatology is an authoritative forum for key opinion leaders across medicine, government, and health systems to influence clinical practice, explore global policy, and inform constructive, positive change worldwide. The Lancet Gastroenterology & Hepatology publishes papers that reflect the rich variety of ongoing clinical research in these fields, especially in the areas of inflammatory bowel diseases, NAFLD and NASH, functional gastrointestinal disorders, digestive cancers, and viral hepatitis.